Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study
- Citation:
- Leuk Lymphoma vol 49 (11) 2081-2090
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- Parents:
- 735
- Children:
- None
- Pharmas:
- Grants:
- N01 CA004919, U10 CA032291, CA33601, CA58348, CA77597, CA04457, CA11789, U10 CA077658, U10 CA004919, CA77406, CA35113, CA32291, CA41287, U10 CA035279, CA03927, U10 CA031946, U10 CA033601, CA60138, U10 CA077597, CA35279, U10 CA077440, CA77440, U10 CA105409, U10 CA041287, U10 CA035113, U10 CA047559, CA105409, CA04326, CA21060, CA47559, CA77658, CA016254, CA31946, U10 CA003927, CA07968
- Corr. Author:
- Authors:
- Eric D. Hsi Sin-Ho Jung Raymond Lai Jeffrey L. Johnson James R. Cook Dan Jones Sven Devos Bruce D. Cheson Lloyd E. Damon Jonathan Said
- Networks:
- Study
- CALGB-59909
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Mantle cell lymphoma, prognosis, Ki67, PIM1, clinical trial, transplant